BROADWAY: Obicetrapib Preserves Kidney Function, Prevents CKD, With Stephen Nicholls, MD

8 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Patients with high cardiovascular risk receiving CETP inhibition with obicetrapib saw preserved kidney function in addition to increased HDL-C, according to the recent BROADWAY trial.
These data were presented at the American College of Cardiology (ACC) Scientific Sessions 2026 in New Orleans, Louisiana, by Stephen Nicholls, MD, director of the Monash Velos Accelerator, program director of MonashHeart, Intensive Care and Victorian Heart Hospital, and director of the Monash Victorian Heart Institute at Monash Health.
In an interview with HCPLive, Nicholls discusses the investigational oral CETP inhibitor's effects on kidney health, potentially due to its capacity for lowering HDL-C.

Read the full article here: https://www.hcplive.com/view/broadway-obicetrapib-preserves-kidney-function-prevents-ckd-with-stephen-nicholls-md

Key Timestamps
00:00:01 Intro
00:00:08 Study Overview

#cardiology #ckd #cholesterol #acc26
Categoria
Cardiology
Commenta per primo questo video.

Prossimo